deoxycytidine has been researched along with Weight Loss in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, J; Correa Ordonez, I; Davis, M; Vanenkevort, E; Varun, S; Wojtowicz, M; Young, A | 1 |
| Aquilini Mummolo, A; Bruno, G; Cincione, RI; Conteduca, V; Giordano, G; Landriscina, M; Lizzi, V; Losavio, F; Pacilli, M; Piscazzi, A; Senia, T | 1 |
| Adham, M; Boschetti, G; Castel-Kremer, E; Charlois, AL; Chopin-Laly, X; Comte, B; De Talhouet, S; Graillot, E; Lombard-Bohas, C; Walter, T | 1 |
| Furuhashi, S; Hiraide, T; Kikuchi, H; Kitajima, R; Kiuchi, R; Konno, H; Morita, Y; Sakaguchi, T; Shibasaki, Y; Takeda, M; Takeuchi, H | 1 |
| Alexandre, J; Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Giroux, J; Goldwasser, F; Mir, O | 1 |
| Alsina, M; Aranda, E; Cano, MT; Conde, V; Díaz-Rubio, E; Galán, M; García de Paredes, ML; López, C; Manzano, JL; Martínez Galán, J; Massutí, B; Pachón, V; Reboredo, M; Rivera, F; Salcedo, M; Sastre, J; Serrano, R; Valladares-Ayerbes, M; Yuste Izquierdo, AL | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Dobrila Dintinjana, R; Guina, T; Krznarić, Z | 1 |
| Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM | 1 |
| Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y | 1 |
| Arvanitaki, M; De Maertelaere, V; Demols, A; Gay, F; Hendlisz, A; Maréchal, R; Van Laethem, JL | 1 |
| Davis, MA; Eisbruch, A; Fields, MT; Lawrence, TS; Normolle, D; Orfali, A; Pu, AT | 1 |
1 trial(s) available for deoxycytidine and Weight Loss
| Article | Year |
|---|---|
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Weight Loss | 2015 |
11 other study(ies) available for deoxycytidine and Weight Loss
| Article | Year |
|---|---|
Is Weight Loss During Chemotherapy for Pancreatic Cancer Prognostic?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Weight Loss | 2023 |
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Nutritional Support; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Retrospective Studies; Weight Loss | 2023 |
An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Female; Gemcitabine; Geriatric Assessment; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Weight Loss | 2018 |
Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
Topics: Aged; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Analysis; Tegafur; Treatment Outcome; Weight Loss | 2019 |
Nutritional status is superior to the ECOG performance status in predicting the dose-intensity of the GEMOX chemotherapy regimen in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; C-Reactive Protein; Deoxycytidine; Dose-Response Relationship, Drug; Female; Humans; Male; Malnutrition; Middle Aged; Neoplasms; Nutritional Status; Organoplatinum Compounds; Retrospective Studies; Risk Assessment; Weight Loss | 2013 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
Nutritional and pharmacologic support in patients with pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Appetite Stimulants; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Megestrol Acetate; Middle Aged; Nutritional Support; Pancreatic Neoplasms; Weight Loss | 2008 |
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Weight Loss | 2011 |
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
Topics: Animals; Cachexia; Capecitabine; Cell Line; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hypercalcemia; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Parathyroid Hormone-Related Protein; Tumor Cells, Cultured; Weight Loss | 2007 |
Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Weight Loss | 2007 |
Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Lip; Mice; Mice, Inbred C3H; Mouth Mucosa; Radiation Tolerance; Radiation-Sensitizing Agents; Weight Loss | 2000 |